Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 70 of the 71 references it cites were found in a registry or an index, and 1 are not checked yet.

ApoCIII as a Cardiovascular Risk Factor and Modulation by the Novel Lipid-Lowering Agent Volanesorsen

Rocha, Natalia A., East, Cara, Zhang, Jun, McCullough, Peter A. · 2017 · Current Atherosclerosis Reports

Abstract

Purpose of review Apolipoprotein CIII (ApoCIII) is now recognized as a key regulator in severe hypertriglyceridemia, chylomicronemia, and conditions of triglyceride-rich lipoprotein (TRL) remnant excess due to its inhibition of lipoprotein lipase (LPL) and hepatic lipase, leading to decreased hepatic reuptake of TRLs, as well as enhanced synthesis and secretion of VLDL from the liver. ApoCIII gain-of-function mutations are associated with atherosclerosis and coronary heart disease (CHD), and contribute to the development of cardiometabolic syndrome, hypertriglyceridemia, and type 2 diabetes mellitus. Conversely, loss-of-function mutations in ApoCIII are associated with lower levels of plasma triglycerides (TG), attenuation of vascular inflammatory processes such as monocyte adhesion and endothelial dysfunction, and potentially, a reduction in the incidence and progression of atherosclerosis and cardioprotection.Recent findings Evidence is now emerging that volanesorsen, a second-generation antisense oligonucleotide drug targeting ApoCIII messenger RNA resulting in decreases in TG in patients with familial chylomicronemia syndrome, severe hypertriglyceridemia, and metabolic dyslipidemia with type 2 diabetes giving support to the hypothesis that ApoCIII is a powerful inhibitor of LPL, and when reduced, endogenous clearance of TRLs can result in substantial reductions in TG levels. Discovery of the ApoCIII inhibitor volanesorsen opens a new era of lipid-lowering drugs for reduction in TG and potentially for reduction in LDL-C. Herein, this review will provide an update on the pathophysiology of ApoCIII-linked atherosclerosis and the development of the first drug to target ApoCIII, volanesorsen, as a promising lipid-lowering agent.

Overview

Integrity signals

Registry

Crossref · 10.1007/s11883-017-0697-3

Cites

70 of 71 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 71 references

Cited by

See all 58

Metadata

Authors
Rocha, N. A., East, C., Zhang, J., & McCullough, P. A.
Affiliations
Baylor University Medical Center (US)
Venue
Current Atherosclerosis Reports
Published
2017-11-09
Volume
19
Issue
12
Pages
62-62
ISSN
  • 1523-3804 (ISSN-L)
  • 1534-6242
OpenAlex
W2767439026
Cited by
54
References
71
Citations by year
2026: 5 · 2025: 6 · 2024: 2 · 2023: 3 · 2022: 8 · 2021: 10 · 2020: 6 · 2019: 5 · 2018: 8 · 2017: 1
FWCI
0.77
Type
journal article
Language
en
Open access
closed
Locations
  • Current Atherosclerosis Reports (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
apolipoprotein C-III, volanesorsen, antisense oligonucleotides, severe hypertriglyceridemia, familial chylomicronemia syndrome, triglyceride-rich lipoproteins, lipoprotein lipase inhibition, hepatic lipase, atherosclerosis, coronary artery disease, cardiometabolic syndrome, type 2 diabetes, lipid-lowering therapy, endothelial dysfunction, LDL cholesterol
MeSH terms
Hypolipidemic Agents, Cardiovascular Diseases, Humans, Oligonucleotides, Risk Factors, Oligonucleotides, Antisense, Dyslipidemias, Atherosclerosis, Apolipoprotein C-III

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: ApoCIII as a Cardiovascular Risk Factor and Modulation by the Novel Lipid-Lowering Agent Volanesorsen. https://app.cochat.ai/papers/10.1007/s11883-017-0697-3
The paper
Rocha, N. A., East, C., Zhang, J., & McCullough, P. A. (2017). ApoCIII as a Cardiovascular Risk Factor and Modulation by the Novel Lipid-Lowering Agent Volanesorsen. Current Atherosclerosis Reports. https://doi.org/10.1007/s11883-017-0697-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.